-
Mashup Score: 0
With more CAR-T therapies being approved or receiving expanded indications, balancing access, cost and risk management is crucial but very challenging, experts said at the AMCP 2025 annual meeting.
Source: www.clinicaloncology.comCategories: General Medicine NewsTweet
-
Mashup Score: 0
The FDA approved tafasitamab (Monjuvi, Incyte) with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma (FL).
Source: www.clinicaloncology.comCategories: General Medicine NewsTweet-
The FDA approved tafasitamab (Monjuvi, Incyte) with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma (FL). https://t.co/tf5JxTxnwi https://t.co/WUFpuGE8ei
-
-
Mashup Score: 0ASCO Meeting: Enhertu + Perjeta Potential First-Line Combo for Metastatic Breast Cancer - 11 day(s) ago
Trastuzumab deruxtecan combined with Perjeta may become first-line therapy for people with metastatic HER2-positive breast cancer, suggests an interim analysis of the phase 3 DESTiNY-Breast09 trial.
Source: www.clinicaloncology.comCategories: General Medicine NewsTweet-
Trastuzumab deruxtecan combined with Perjeta may become first-line therapy for people with metastatic HER2-positive breast cancer, suggests an interim analysis of the phase 3 DESTiNY-Breast09 trial. https://t.co/4iBUEc90b9 https://t.co/B0g1qMAwlm
-
-
Mashup Score: 0
Fecal microbiota transplantation may enhance the effectiveness of immunotherapies by reducing gut dysbiosis, according to a presentation at the 2025 ASCO Annual Meeting.
Source: www.clinicaloncology.comCategories: General Medicine NewsTweet-
Fecal microbiota transplantation may enhance the effectiveness of immunotherapies by reducing gut dysbiosis, according to a presentation at the 2025 ASCO Annual Meeting. https://t.co/FakMCcQTkz https://t.co/bqlcQc7Aja
-
-
Mashup Score: 0Many Ways to Guard Against Cyberattacks - 15 day(s) ago
Pharmacy leaders sometimes focus on strategies for increasing revenues as cybersecurity takes a back seat.
Source: www.clinicaloncology.comCategories: General Medicine NewsTweet-
Pharmacy leaders sometimes focus on strategies for increasing revenues as cybersecurity takes a back seat. https://t.co/sLs4CD0LMr https://t.co/wWu6CDD2IU
-
-
Mashup Score: 0FDA Approves Neoadjuvant and Adjuvant Keytruda for Resectable, Locally Advanced Head and Neck SCC - 15 day(s) ago
This is the first approval for HNSCC in six years and the first overall perioperative approval for locally advanced HNSCC.
Source: www.clinicaloncology.comCategories: General Medicine NewsTweet-
This is the first approval for HNSCC in six years and the first overall perioperative approval for locally advanced HNSCC. https://t.co/QJu5IC8ts9 https://t.co/ufFxAQ8YIw
-
-
Mashup Score: 0
In an ongoing phase 3 trial, rusfertide (Takeda/Protagonist Therapeutics), a first-in-class hepcidin mimetic, reduced symptoms and the need for phlebotomy in patients with polycythemia vera.
Source: www.clinicaloncology.comCategories: General Medicine NewsTweet-
In an ongoing phase 3 trial, rusfertide (Takeda/Protagonist Therapeutics), a first-in-class hepcidin mimetic, reduced symptoms and the need for phlebotomy in patients with polycythemia vera. https://t.co/S18SRrau1o https://t.co/2TTd7gPCei
-
-
Mashup Score: 0Zusduri Approved for Recurrent Low-Grade Intermediate-Risk Non–Muscle-Invasive Bladder Cancer - 15 day(s) ago
The FDA has approved mitomycin intravesical solution (Zusduri, UroGen Pharma) for adult patients with recurrent low-grade intermediate-risk non–muscle-invasive bladder cancer.
Source: www.clinicaloncology.comCategories: General Medicine NewsTweet-
The FDA has approved mitomycin intravesical solution (Zusduri, UroGen Pharma) for adult patients with recurrent low-grade intermediate-risk non–muscle-invasive bladder cancer. https://t.co/n5kxq0TdoR https://t.co/cMGpgFFCvb
-
-
Mashup Score: 4FDA Approves Ibtrozi for ROS1-Positive NSCLC - 17 day(s) ago
The FDA approved taletrectinib (Ibtrozi, Nuvation Bio), a kinase inhibitor, for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
Source: www.clinicaloncology.comCategories: General Medicine NewsTweet-
The FDA approved taletrectinib (Ibtrozi, Nuvation Bio), a kinase inhibitor, for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). https://t.co/xsAVUgTyRy https://t.co/gUGp9I4aOS
-
-
Mashup Score: 0Barriers to Prescribing Effective Recurrent CDI Therapies - 17 day(s) ago
There may be barriers, including insurance denials, to using products that are effective for recurrent Clostridioides difficile infections.
Source: www.clinicaloncology.comCategories: General Medicine NewsTweet-
There may be barriers, including insurance denials, to using products that are effective for recurrent Clostridioides difficile infections. https://t.co/FR6QDTHVkG https://t.co/a4NzJXf5Lp
-
With more CAR-T therapies being approved or receiving expanded indications, balancing access, cost and risk management is crucial but very challenging, experts said at the AMCP 2025 annual meeting. https://t.co/kHACuCNn2N https://t.co/e98Wr63e4v